Form 4: Allogene Therapeutics Executive Sells Shares to Cover Tax Obligations

Timothy L. Moore, Chief Technical Officer of Allogene Therapeutics, sold 17,360 shares of common stock on April 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 22, 2024, Timothy L. Moore, the Chief Technical Officer of Allogene Therapeutics, sold 17,360 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.4671.
• The price ranged from $3.44 to $3.49 per share.
• Following the transaction, Moore still beneficially owns 265,459 shares of Allogene Therapeutics.
• The sale was mandated by Allogene's equity incentive plan, which requires a 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction is not necessarily indicative of a change in the executive's confidence in the company.

Key Dates